News

How can Open-Innovation be a powerful driver for One Health dynamics?

 

As diverse as they are complementary, our panelists will address the common challenges faced by human and animal health and highlight the benefits and limits of open-innovation collaborations across this sectors.

The solutions to these common challenges may be provided by the One Health dynamics and be powerful drivers for tomorrow’s innovations. Cross sector collaborations could lead to a faster development of health tools and technologies that will both protect against infectious diseases while helping tackle some of the major chronic disease challenges of the 21^st century.

 

To address this exciting cross-sector session :

• Pineau Thierry (moderator) INRA Animal Health Metaprogram Director, INRA UNIVERSITY, FRANCE
• Arnouts Sven, Business development Manager , PROVAXS, BELGIUM
• Dubruque Matthieu, COO, Oncovet Clinical Research, France
• Hanon Emmanuel, Senior Vice President, GSK VACCINES, UK
• Dieuzy-Labaye Isabelle, Director, Strategic Alliances, ZOETIS, FRANCE

 

 

Scheduled December 1st at 2pm, we are already looking forward to listening to these heavy league speakers !

Discover the full speaker list here, and the conference program here

Want to speak at BioFIT? Contact us!

IDEA Summit, European event dedicated to translational research on diabetes is organized by Eurasanté, NHL cluster & Lund University and will be hosted by BioFIT. You want to learn more about IDEA Summit & BioFIT 2015?

We will attend EASD 51st Annual Meeting 2015

On Wednesday 2^nd, in Strasbourg’s PMC, will be addressed within BioFIT, the hot topic of Crowd-funding’s place in Drug Development. 

Chaired by Cormac Sheridan, journalist at BioWorld today, Ireland, this session will confront the opinions of Mohammed Charki, Research and Development Partnerships Director of Sanofi, Ajan Reginald, Chief Executive of Cell Therapy, Daniel Olivier, CEO of Capital Cell, and Fabrice Beauchêne, CEO of My Pharma Company

Does it have a place or does it not ? This session is digging for more than a simple yes/no answer, chairman Cormac Sheridan described the session in these terms :

“To many of us, drug development is just about the last field one would associate with crowdfunding. Although it has become a useful adjunct to traditional methods of raising money for cultural and philanthropic initiatives and even for for-profit tech ventures, crowdfunding does not seem to fit the more formal fundraising culture of biotechnology. The capital requirements and the long-term investment horizons of drug development both militate against the buzzy ‘viral’ culture of crowdfunding. And yet, as a recent report from the Berlin-based research consultancy Biocom AG confirms, a growing number of European life sciences firms, particularly in France and the UK, has started to explore its possibilities. Biocom identified 42 campaigns (in biotech and medtech), which raised a combined €23 million over the past five years. Ten firms raised €1 million or more. Crowdfunding platforms with a specialist focus on life sciences have now started to emerge, and some are introducing new investment models. Does this represent a passing fad? Or the beginning of something big? How will stock exchanges (the ultimate crowdfunding platforms) engage with crowdfunding platforms? Which biotech companies should engage with them? And how? Join us to explore the potential for crowdfunding in drug development.”

What do you think ? Is there a place for crowd-funding in drug development ? Come share your opinion with our panel, we are already looking forward to attending this hot debate !

Discover the full speaker list here, and the conference program here

Want to speak at BioFIT? Contact us

You’re curious about BioFIT 2015 and you want to discover the lastest news ?

All about BioFIT – from all the details of the Conferences Program, the Presenting Technologies sessions and the Hosted Events to the Full Agenda and lot more.

You will now everything about the leading european partnering event dedicated to tech transfer and open innovation in Life Sciences.

So don’t wait and download it !

 

Download Oral Presentations Agenda

Who drives innovation in Life Sciences? Academia or industry?

Scheduled on December 1^st to start in style, the Plenary session will gather the best and brightest to answer the sector’s raising concern!

Steering Committee member Ivan Baines, Chief Operating Officer, Max Planck Institute of Molecular Cell Biology and Genetics (DE) described the session in these terms :

Between arm-wrestling and handshake, finding a balance in academia-industry collaborations is mandatory in order to foster innovation. But is that as simple as it sounds? Where does innovation come from in the life sciences industry? Who really drives it? Can one partie succeed without the other?  Can we talk about driving and serving? Let’s analyze the complex relationship of these two parties and the numerous elements involved through our panelists’ expertise:

• MODERATOR : John Carroll, Editor-in-chief, FierceBiotech, USA
• Jochen Maas, General Manager, Research & Development Germany, Sanofi, Germany
• Marisol Quintero,CEO, BiOncotech Therapeutics, Spain
• Kurt Hertogs, Head Platform Innovation & Incubator Strategy , Johnson & Johnson, United-Kingdom
• Alexander von Gabain, Deputy Vice-Chancellor for Innovation and Corporate Alliances, Karolinska Institute, Sweden

We are looking forward to attend this session that promises a great debate! Come and join us!

Discover the full speaker list here, and the conference program here

Want to speak at BioFIT? Contact us!

BioFIT team will be pleased to attend NLS Days 2015

on September 9th & 10th in Stockholm, Sweden.

NLS Days is the largest Life Sciences invest and partnering meeting in the Nordic region; Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends.

Based on cutting-edge and advanced partnering and networking tools, Nordic Life Science Days showcases the best the Nordic region has to offer and attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities, NLS Days is the perfect occasion to come and meet us!

Take advantage of that perfect opening to get an extensive overview of BioFIT activities, or just have a chat with our team! 😉

Four hands on the steering wheel? How are academia/industry alliances managed?

3 high-level experts already confirmed to share their expertise with us

• Jan Van der Schueren, Discovery Site Head, Galapagos NV , BE
• Jutta Roth, Business Development Manager,  University of Oxford, UK
• Maria Bobadilla, Senior Director, Extending Innovation Network, Roche, CH

 

Scheduled December 2^nd at 4 pm, the session will address the challenge to create a business model that protects both parties, how to make it flexible enough to fuel innovation and decide what kind of structural leadership will be the most effective in running these alliances.

The decision on who will control the direction of the collaboration is as important as the structure of the agreement itself.

Will it be a joint steering committee with equal representation, will it be individuals who understand both parties (academics and industry)?

What are the concerns expressed by both parties when choosing one or the other option?

We are already are eager to see the aftermath of this thrilling session!

 

Discover the full speaker list here, and the conference program here

Want to speak at BioFIT? Contact us!

For its 4th edition BioFIT will gather 1,300 international leaders from :

• pharma,
• biotech,
• medtech,
• IVD companies,
• investors,
• as well as professionals from technology transfer
• and academia.

The perfect mix of attendees to boost up licensing deals and research collaborations!

Take time to check out the list of attendees. *

They all will be there, will you too?

*This list is updated on a weekly basis.

US vs Europe: how do VCs asses risk?

BioFIT team found complementary profiles to adress the topic while opposing their methods :

• Sara Nunez-Garcia, Associate, Soffinova, UK
• Garold Breit, CEO Breit Ideas, USA
• YenShen Huang, Senior Assistant Vice-President, Diamond Capital, TW

Scheduled December 1st at 2pm, our confirmed speakers will share their point of view alongside  other fellows.

We are already looking forward to listening to these heavy league speakers !

Discover the full speaker list here, and the conference program here

Want to speak at BioFIT? Contact Ramona Pirv-Chicireanu, Conference Coordinator